EGFR and lung adenocarcinoma: The discrepancy of our present investigation with previous studies regarding the better outcome in ICI-untreated patients may be attributed to the inclusion in our current study of an increased number of patients with mutant epidermal growth factor receptor (EGFR)-positive lung adenocarcinoma in the DTX/RAM group without previous history of ICI and an increased number of cases of squamous cell carcinoma in the DTX-treated group [21,22,23].